London, UK, 19 October 2023 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce that it has won the award for Best Poster at the 14th Annual #WorldADC conference, San Diego, California, held from October 16-19, 20231.
The poster showcased new data on the preclinical efficacy of Myricx’ proprietary N-Myristoyltransferase inhibitor (#NMTi) payload platform and was selected against a large field judged by experts in the ADC field.
Accepting the award, CEO, Dr Robin Carr said: “World ADC is the preeminent gathering of experts in the ADC field. This award is an endorsement of the huge potential our platform has to create an important new class of ADC medicines.”
The data presented showed complete tumour regressions across a range of solid tumour xenograft models for NMTi-ADCs targeting three clinically validated tumour-associated antigens (B7-H3, TROP2 and HER2), as well as excellent bystander activity, and encouraging preliminary safety findings.
Congratulations to Myricx team and authors on the poster who have contributed to this work: Robin Carr, Josephine Walton, Folake Orafidiya, Nikki D’Arcy, Francesco Falciani, Sarah Spear, Katie Tyson, Iain McNeish, Tim Ritchie, Andy Bell, Ed Tate, and Roberto Solari.
1. Poster Details:
Title: N-Myristoyltransferase (NMT) inhibitors as completely novel payloads for Antibody Drug Conjugates, deliver extensive tumor regression at well tolerated doses.
Presented by: Dr Robin Carr, CEO Myricx Bio
Session: Scientific Program, Tuesday October 17, Evening Session
A copy of the poster is available on our website – HERE
Notes to Editors:
About Myricx Bio – www.myricxbio.com
Myricx Bio (“Myricx”) is a UK biotech company focused on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.
NMT is an enzyme that adds a specific lipid modification to a number of protein targets key to cancer cell survival. Myricx is advancing a pipeline of ADCs to address serious unmet needs in oncology based on its NMT inhibitor (NMTi) payload chemistry platform and has demonstrated excellent preclinical efficacy and safety across multiple solid tumour associated antigens and cancer cell types.
Based in London, Myricx is a spin out from Imperial College London and the Francis Crick Institute with investment from Sofinnova Partners and Brandon Capital Partners.
Follow us on LinkedIn
For further information please contact
At the Company
Dr Robin Carr, CEO
Sue Charles, Charles Consultants
+44 (0)7986 726585